Clostridium diagnostics market to reach US$ 7.8B by 2032

The global clostridium diagnostics market is projected to secure US$ 7.8 Billion by 2032 while recording a CAGR of 12.2% during the forecast period. The growth of the market can be attributed to the growing prevalence of clostridium-related diseases and the growing awareness campaigns launched by various authorities.

There has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects.

Awareness campaigns are expected to play important role in driving the market during the forecast period. For instance, the ‘See C. diff’ campaign, launched by Peggy Lillis Foundation in December 2020, attained its objective by reaching more than 250,000 Americans. The organization launched the ‘See C. diff’ to commemorate C.diff Awareness Month in 2019, and reached about 80,000 people.

The launch of new vaccines in the market is another vital factor driving the market during the forecast period. For instance, in August 2021, Huvepharma Canada Corporation Inc. launched a new vaccine that has been shown to be effective against necrotic enteritis (NE) due to Clostridium perfringens type A in broiler chickens.

In addition, emerging companies such as, Acurx Pharmaceuticals, Cubist Pharmaceuticals, Endo Aesthetics, Avisa Pharma, and MGB Bio Pharma are expected to make a significant contribution in developing the market during the forecast period. However, lack of awareness and scarcity of resources in developing countries are expected to hamper the market growth during the forecast period. Also, the high costs involved in R&D and vaccine manufacturing are expected to be other factors hindering the market growth in the assessment period.

However, growing partnerships among players are projected to counter the hampering factors and boost the market. For instance, in March 2021, Peggy Lillis Foundation for Clostridium difficile infections announced a partnership with Ferring Pharmaceutical through a new sponsorship to assist new and existing patient advocacy initiatives.

Key takeaways from the market study:

• The immunoassays technology is expected to dominate the global clostridium diagnostics market at a CAGR of 11.6% during 2022-2032
• The clostridium diagnostics market in the U.S is anticipated to display a CAGR of 11.8% during the forecast period
• The U.K clostridium diagnostics market is predicted to hold a market value worth US$ 330 Million by 2032
• The Japanese clostridium diagnostics market is estimated at a CAGR of 11.1% during the forecast period.

Key segments profiled in the global clostridium diagnostics market
Clostridium diagnostics market by technology:

• Immunoassays-based clostridium diagnostics
• Molecular clostridium diagnostics

Clostridium diagnostics market by end user:

• Clostridium diagnostics in hospitals
• Clostridium diagnostics in government diagnostics laboratories
• Clostridium diagnostics in independent laboratories

Clostridium diagnostics market by product:

• Clostridium difficile diagnostics
• Clostridium perfringens diagnostics
• Clostridium botulinum diagnostics
• Clostridium tetani diagnostics
• Clostridium sordell diagnostics

Clostridium diagnostics market by region:

• North America Clostridium Diagnostics Market
• Asia Pacific Clostridium Diagnostics Market
• Europe Clostridium Diagnostics Market
• Middle East & Africa Clostridium Diagnostics Market
• Latin America Clostridium Diagnostics Market

Future Market Insights